Recombinant Human Thioredoxin-Interacting Protein (TXNIP) Protein (His-B2M)

Beta LifeScience SKU/CAT #: BLC-00478P
Greater than 85% as determined by SDS-PAGE.
Greater than 85% as determined by SDS-PAGE.

Recombinant Human Thioredoxin-Interacting Protein (TXNIP) Protein (His-B2M)

Beta LifeScience SKU/CAT #: BLC-00478P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Thioredoxin-Interacting Protein (TXNIP) Protein (His-B2M) is produced by our E.coli expression system. This is a full length protein.
Purity Greater than 85% as determined by SDS-PAGE.
Uniprotkb Q9H3M7
Target Symbol TXNIP
Species Homo sapiens (Human)
Expression System E.coli
Tag N-6His-B2M
Target Protein Sequence MVMFKKIKSFEVVFNDPEKVYGSGEKVAGRVIVEVCEVTRVKAVRILACGVAKVLWMQGSQQCKQTSEYLRYEDTLLLEDQPTGENEMVIMRPGNKYEYKFGFELPQGPLGTSFKGKYGCVDYWVKAFLDRPSQPTQETKKNFEVVDLVDVNTPDLMAPVSAKKEKKVSCMFIPDGRVSVSARIDRKGFCEGDEISIHADFENTCSRIVVPKAAIVARHTYLANGQTKVLTQKLSSVRGNHIISGTCASWRGKSLRVQKIRPSILGCNILRVEYSLLIYVSVPGSKKVILDLPLVIGSRSGLSSRTSSMASRTSSEMSWVDLNIPDTPEAPPCYMDVIPEDHRLESPTTPLLDDMDGSQDSPIFMYAPEFKFMPPPTYTEVDPCILNNNVQ
Expression Range 1-391aa
Protein Length Full Length
Mol. Weight 58.2 kDa
Research Area Others
Form Liquid or Lyophilized powder
Buffer Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function May act as an oxidative stress mediator by inhibiting thioredoxin activity or by limiting its bioavailability. Interacts with COPS5 and restores COPS5-induced suppression of CDKN1B stability, blocking the COPS5-mediated translocation of CDKN1B from the nucleus to the cytoplasm. Functions as a transcriptional repressor, possibly by acting as a bridge molecule between transcription factors and corepressor complexes, and over-expression will induce G0/G1 cell cycle arrest. Required for the maturation of natural killer cells. Acts as a suppressor of tumor cell growth. Inhibits the proteasomal degradation of DDIT4, and thereby contributes to the inhibition of the mammalian target of rapamycin complex 1 (mTORC1).
Subcellular Location Cytoplasm.
Protein Families Arrestin family
Database References

HGNC: 16952

OMIM: 606599

KEGG: hsa:10628

STRING: 9606.ENSP00000358323

UniGene: PMID: 29852169

  • Expression of TXNIP2 isoform, not TXNIP1, is upregulated in leukocytes of patients with acute myocardial infarction. PMID: 30034557
  • Thioredoxin-interacting protein (TXNIP) is highly induced in retinal vascular endothelial cells under diabetic conditions. Data (including data from studies using knockout mice) suggest that TXNIP in retinal vascular endothelial cells plays role in diabetic retinal angiogenesis via VEGF/VEGFR2 and Akt/mTOR signaling. (VEGFR2 = vascular endothelial growth factor receptor-2) PMID: 29203232
  • miR-20a could negatively regulate TLR4 and NLRP3 signaling to protect human aortic endothelial cells from inflammatory injuries. PMID: 29653364
  • Results found the mRNA level of TRX-1 was significantly decreased (p<0.005), while the mRNA levels of TBP-2, COX-2, and TNF-alpha were significantly increased in the placentas in preeclampsia when compared to the normal group. PMID: 29999276
  • Consistent with its enhanced expression in Laron syndrome, we provide evidence that TXNIP gene expression is negatively regulated by IGF1. PMID: 29339473
  • TXNIP contributes to the dysregulation of tubular autophagy and mitophagy in diabetic nephropathy through activation of the mTOR signaling pathway. PMID: 27381856
  • This study thus characterizes ERK-mediated suppression of TXNIP as a presently unreported mechanism by which ap junctions regulate cell behaviors. PMID: 28694028
  • Results indicate an internal ribosome entry sites (IRESes) within the thioredoxin-interacting protein (TXNIP) protein; 5' untranslated region (5'UTR), and regulatory IRES trans-acting factors. PMID: 29378331
  • The data of this study suggested that TXNIP blocked autophagic flux and induced alpha-synuclein accumulation through inhibition of ATP13A2. PMID: 28755477
  • Compared with normal tissues, TXNIP expression was significantly decreased in human breast cancer tissues and canine mammary tumors, along with tumor progression. PMID: 29524408
  • This finding suggested statistically significant role of interaction of TXNIP and AF1q polymorphisms (TXNIP-rs2236566, TXNIP-rs7211, and AF1q-rs2769605) in schizophrenia susceptibility. PMID: 27510506
  • summarize the current state of our understanding of TXNIP biology, highlight its role in metabolic regulation and raise critical questions that could help future research to exploit TXNIP as a therapeutic target PMID: 28137209
  • intracellular TXNIP protein is a critical regulator of activation of the fructose-induced NLRP3 inflammasome PMID: 28326454
  • This study provides insight into the molecular mechanisms of TXNIP overexpression in liver cancer cell survival and apoptosis and indicated that TXNIP may be a novel promising agent for liver cancer treatment. PMID: 28440491
  • Study showed that the expression of TXNIP was significantly increased in RNF2 knockdown prostate tumor cells and that TXNIP is an important downstream target of RNF2. PMID: 28029659
  • Depletion of glycolytic intermediates led to a consistent decrease in TXNIP expression in response to 1,25(OH)2D3, an effect that coincided with the activation of AMPK signaling and a reduction in c-MYC expression. PMID: 28651973
  • We found no evidence of decreased TXNIP DNA methylation or increased gene expression in metabolic target tissues of offspring exposed to maternal diabetes. Further studies are needed to confirm and understand the paradoxical SAT TXNIP DNA methylation and gene expression changes in O-GDM subjects PMID: 29077742
  • the association of TXNIP (thioredoxin-interacting protein) with NLRP3 induced by ROS promoted NLRP3 inflammasome activation in senescent HUVEC endothelial cells PMID: 28064010
  • histone acetylation serves as a key regulator of glucose-induced increase in TXNIP gene expression PMID: 27989964
  • thioredoxin-interacting protein deficiency alleviates diabetic renal lipid accumulation through regulation of Akt/mTOR pathway PMID: 27497988
  • High expression of TXNIP indicates a lower pathological grade of meningnioma, and is also associated with longer recurrence-free time. PMID: 28243945
  • All-trans retinoic acid plays a key role in inhibition of hepatic stellate cell activation via suppressing TXNIP expression, which reduces oxidative stress levels. PMID: 28322443
  • Study shows that TXNIP expression is down-regulated in new Multiple Sclerosis (MS) patients compared to controls and might be implicated in pathogenesis of the disease. PMID: 28844667
  • TXNIP Single nucleotide polymorphisms may individually and cumulatively affect CAD risk through a possible mechanism for regulating TXNIP expression and gene-environment interactions. PMID: 27470124
  • Taken together, our results firstly reveal that TMAO induces inflammation and endothelial dysfunction via activating ROS-TXNIP-NLRP3 inflammasome, suggest a likely mechanism for TMAO-dependent enhancement in atherosclerosis and cardiovascular risks. PMID: 27833015
  • results suggest that TXNIP is required early in the apoptotic-inducing pathway resulting from r-Moj-DM binding to the alphav integrin subunit PMID: 27567705
  • Hypoxia suppresses thioredoxin binding protein-2 gene expression, which may ultimately alter placental development. PMID: 27762463
  • Heme oxygenase rs2071749 polymorphism was positively associated with obesity in Mexicans. PMID: 27274779
  • These data identify novel Txnip protein interactions. PMID: 27437069
  • Glucose exerts strong stimulatory effects on activation histone marks while having inhibitory effects on repression marks in the promoter of the TXNIP gene, and this was associated with a marked increase in expression of the proinflammatory gene in kidney. PMID: 26806835
  • No evidence that SNPS in TXNIP has effect, but the rs4485648 polymorphism of the TrxR2 gene might exert an independent effect on the development of Diabetic retinopathy. PMID: 26763822
  • An association has been found between the TXNIP gene methylation pattern and type 2 diabetes mellitus in ischemic stroke patients through epigenetic mechanisms, related to sustained hyperglycemia levels with HbA1c >/= 7%. PMID: 26643952
  • These findings thereby provide new mechanistic insight into the regulation of TXNIP and beta-cell biology and reveal novel links between proinflammatory cytokines, carbohydrate response element binding protein-mediated transcription, and microRNA signaling. PMID: 26858253
  • The crystal structure of the complex between a phosphorylated PPxY motif of TXNIP and the SH2 domain of Vav2 reveals a conserved recognition mechanism. PMID: 26919541
  • Activation of the miR-373-TXNIP-HIF1alpha-TWIST signaling axis is correlated with a worse outcome in patients with breast cancer. PMID: 26196741
  • Metformin down-regulates high-glucose-induced TXNIP transcription by inactivating ChREBP and FOXO1 in endothelial cells, partially through AMP-activated protein kinase activation PMID: 26147751
  • Foam cell-released 4-hydroxnonenal activates PPARdelta in Vascular endothelial cells, leading to increased TXNIP expression and consequently to senescence. PMID: 25754218
  • our data support the hypothesis that TXNIP is an effective target for the treatment of breast cancer. PMID: 25812606
  • Expression of TXNIP was up-regulated in all three NSCLC cell lines. PMID: 25854388
  • Data identify the metastasis suppressor TXNIP as new target of miR-224/miR-452 that induces feedback inhibition of E2F1 and show that miR-224/452-mediated downregulation of TXNIP is essential for E2F1-induced EMT and invasion PMID: 25341426
  • HG-induced NADPH oxidase activation is driven by TXNIP which subsequently triggers NALP3 inflammasome activation in podocytes and ultimately led to podocyte injury PMID: 25834832
  • Suggest that TXNIP plays a critical role in anti-Her-1/Her-2 treatment and may be a potential prognostic marker in breast cancer. PMID: 25605021
  • The expression of TXNIP was significantly higher in normal-weight type- 2 diabetic patients than in obese ones. PMID: 25726203
  • The inhibition of TRX by TXNIP is mediated by an intermolecular disulphide interaction resulting from a novel disulphide bond-switching mechanism. This bond dissociates in the presence of high concentrations of reactive oxygen species. PMID: 24389582
  • The protein expression level of TXNIP was negatively correlated with the level of miR-373 in MCF-7 cells and in breast cancer tissue of various migration and invasion abilities. TXNIP was regulated by miR-373. PMID: 26122224
  • data suggest that loss of the p53 tumor suppressor cooperates with Mychigh/TXNIPlow-driven metabolic dysregulation to drive the aggressive clinical behavior of TNBC. PMID: 25870263
  • diabetes was associated with a >30-fold increase in TxnIP gene expression and a 17 % increase in TxnIP protein expression. PMID: 24925443
  • TXNIP has been discovered to control pancreatic B-cell microRNA expression, B-cell function, and insulin production. [Review] PMID: 24911120
  • regulatory relationship between mTOR and the MondoA-TXNIP axis that we propose contributes to glucose homeostasis PMID: 25332233
  • FAQs

    Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

    Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

    Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

    Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

    Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

    Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

    To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

    Recently viewed